|
|
Lexiva (Fosamprenavir, Telzir)
| Brand Name: |
Lexiva |
| Generic Name: |
Fosamprenavir calcium, FPV |
| Adult Single Dose: |
Therapy-naive patients: two 700-mg tablets (twice a day) without
ritonavir OR two 700-mg tablets plus two 100-mg ritonavir capsules
(once a day) OR one 700-mg tablet (twice a day) plus one 100-mg
ritonavir capsule (twice a day)
Protease inhibitor-
experienced patients: one 700-mg tablet (twice a
day) plus one 100-mg ritonavir capsule (twice a day) -- once a day
administration of fosamprenavir plus ritonavir is not recommended in protease
inhibitor-experienced patients)
Adjustment of ritonavir dose only when fosamprenavir plus ritonavir are
administered once a day with efavirenz: two 700-mg tablets (once a
day) plus three 100-mg ritonavir capsules (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
PI |
The Basics
- An Overview of Lexiva (Fosamprenavir, Telzir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Lexiva (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Fosamprenavir (Telzir, Lexiva) (November 13, 2008)
To read PDF, click here
From AIDS InfoNet
- Patient Information About Lexiva (Fosamprenavir, Telzir) (PDF) (October 2008)
From GlaxoSmithKline
- Labeling Update for Lexiva (Fosamprenavir) (December 21, 2007)
From U.S. Food and Drug Administration
- Lexiva (Fosamprenavir) (November 8, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
- Fosamprenavir (908, Lexiva, Telzir) (August 15, 2006)
From AIDS Treatment Data Network
- Lexiva (Fosamprenavir) (May 2005)
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Fosamprenavir (August 2004)
From Project Inform
- Fosamprenavir: A New Protease Inhibitor Option (February 2004)
An interview with Jeffrey Nadler, principal investigator of the pivotal NEAT study.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care
News & Research
- Clinical Trials Using Fosamprenavir (Lexiva) (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
- Literature Citations for Fosamprenavir (Lexiva) (Regularly Updated)
From U.S. National Institutes of Health
- GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
- New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
- Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here
From GlaxoSmithKline
- FDA Approval of Lexiva Oral Suspension and Label Changes for Pediatric Patients and Patients With Hepatic Impairment (June 18, 2007)
From U.S. Food and Drug Administration
- Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
- Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections
|
Advertisement
|
E-Mail
Glossary
Share